Mato just raised pre-seed Read more
Podcast charts
Published by Day One®
What The Health cuts through the BS in health innovation with honest conversations, rants, bants, practical insights, and the people shaping what's next. Less hype. More signal. Hosted by Emily Casey — Director of What The Health, one of Australia's leading health innovation media and communities of 11,000+, and Community & Partnership Lead at Tenmile. Brought to you with Tenmile (www.tenmile.com).
On the charts
Every published chart this podcast appears in, in the snapshot behind this page. Each one links to the chart it came off.
The Mato Topic Intelligence Platform does not report this podcast as charting in a published category in this snapshot.
From the feed
The latest episodes published to this podcast’s own RSS feed. Titles and descriptions are the publisher’s.
One in three people will experience a mental health disorder in their lifetime, PTSD went more than 20 years without a new approved treatment, and spending keeps rising while outcomes keep getting worse. Against that backdrop, Australia has become the first country in the world where psychiatrists can prescribe MDMA and psilocybin. In this episode, host Emily Casey sits down with Dr Michael Winlo, Chief Scientific Officer at Emyria, the company behind the Empax network of psychedelic-assisted therapy clinics. Michael trained as a doctor, spent four years in Palantir's healthcare team in Silicon Valley, then returned to Perth to run a clinical trial site — an experience that convinced him care delivery and evidence generation belong together, and led to Emyria. Michael explains how the two legal treatments actually work. MDMA floods the brain with serotonin and oxytocin, quietens an overactive amygdala and lets patients with post-traumatic stress disorder work through trauma in therapy without being overwhelmed by fear or shame. Psilocybin quietens the default mode network behind rumination and negative self-talk — Michael's metaphor is shaking up a snow globe and letting the snow settle into new patterns — and both drugs open a roughly seven-day window of heightened neuroplasticity that therapy can use. The pair trace the strange history that got us here: MDMA first synthesised by Merck in 1912, psychedelics on the cover of psychiatry journals in the 1960s, roughly 500,000 people given MDMA in therapeutic settings before the war on drugs shut the research down. Charitable funding through MAPS kept the science alive, and the resulting phase 2 and 3 trials left the TGA unable to maintain that these drugs had no therapeutic value — leading to the world-first rescheduling in 2023. Michael then walks through what treatment at an Empax clinic involves: careful screening, a two-therapist dyad that stays with the patient for the whole journey, six-to-eight-hour dosing days in a low-stimulus room, and integration sessions that turn insights into durable habits. Emyria has now treated more than 100 patients, with rapid improvement that appears durable for most — results that have brought funders like Medibank and the Department of Veterans' Affairs on board. The conversation closes on what it will take to make this mainstream: health-economic evidence for a treatment that costs around $10,000 a dosing cycle, the watershed of a first FDA approval, more sensible regulation of who can deliver therapy, and the infrastructure and training to meet demand. Michael argues psychedelics are still under-hyped — used today as a last resort when they may do the most good earlier in a patient's journey — and leaves clinicians with one message: learn with your patients. Guest Dr Michael Winlo is Chief Scientific Officer at Emyria, the ASX-listed company behind the Empax network of psychedelic-assisted therapy clinics, treating post-traumatic stress disorder and treatment-resistant depression under the TGA's Authorised Prescriber Scheme. Trained as a medical doctor, he spent four years in Palantir's healthcare team in Silicon Valley and led Perth's Linear Clinical Research before joining Emyria to build a model of care that treats patients and generates evidence at the same time. Chapters 00:00 Psychedelics return to healthcare 00:57 What Emyria and the Empax clinics do 02:08 From medicine to Palantir and back to Perth 08:32 Why mental health care is falling behind 12:37 What psychedelics actually are 13:55 How MDMA-assisted therapy works 17:44 Psilocybin and the default mode network 21:05 A century of history: from Merck to the war on drugs 24:18 The revival: MAPS, new trials and Australia's rescheduling 27:17 Why psychiatry innovates slowly 29:47 Inside treatment: screening, dosing days and integration 33:33 The data so far: 100+ patients, Medibank and the DVA 35:18 Ketamine and the coming wave of new treatments 36:47 FDA approval and the funding shift 43:30 Emyria's ten-year vision 45:47 Bottlenecks: training, regulation and infrastructure 47:31 Psychedelic therapy in 2035 49:09 Rapid fire: hype, books and one message for clinicians Links and resources Emyria: https://emyria.com/ Empax Centre: https://empaxcentre.com/ TGA — re-scheduling of psilocybin and MDMA, questions and answers: https://www.tga.gov.au/resources/publication/scheduling-decisions-final/notice-final-decision-amend-or-not-amend-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma/re-scheduling-psilocybin-and-mdma-poisons-standard-questions-and-answers MAPS (Multidisciplinary Association for Psychedelic Studies): https://maps.org/ COMPASS Pathways: https://compasspathway.com/ The Beginning of Infinity by David Deutsch: https://en.wikipedia.org/wiki/The_Beginning_of_Infinity Moonshots with Peter Diamandis: https://www.diamandis.com/podcast About the host Emily Casey is the founder of What the Health and host of the show, making major developments in health technology and innovation easier to understand. What the Health is brought to you in partnership with Tenmile Ventures. What the Health is part of Day One Network, the podcast and media network from W2D1 Media: https://dayone.fm/
A survey of more than 1,800 clinicians across 25 countries found 83% had already adopted AI before their workplace had any governance in place. Healthcare, it turns out, is not just adopting AI. It is being redesigned around it. In the second What the Health Wrap, host Emily Casey is joined by Dr Simon Kos, Global Chief Medical Officer at Heidi, and Dr Janice Tan, GP and General Manager of Clinical Innovation at Bupa, to work through what the fortnight's biggest healthcare stories actually mean. Simon uses Heidi's Pressure Points report to bust some long-held myths. Clinicians are not Luddites; get product-market fit right and they will adopt ahead of their own organisations. Product-led growth is not impossible in healthcare. And the idea that everything must run through a single electronic medical record screen does not survive contact with the reality of shadow AI. Janice agrees, arguing that GPs are among the most innovative professionals there are, and that what matters is not clicks or screens but the value exchange. The conversation turns to where this leaves general practice. Both guests expect voice to become the default way information is entered within two years, freeing clinicians for deeper, more present consultations rather than merely shorter ones. Janice makes the point that scribes save time not to compress the visit but to enrich it. Simon argues that scribes should be commoditised, because they are the entry point to something bigger: infusing evidence and decision support into the flow of care. They also examine what happens when patients bring their own AI into the room. OpenAI's launch of Health in ChatGPT, and the broader move by frontier labs into consumer health, could be the single biggest driver of health equity, filling the gap for people who previously had no care at all. But Simon draws a firm line between consumer-grade and clinical-grade health, pointing to the liability caps some providers attach to their advice and the accountability the medical profession is held to. The regulatory framework for quality and safety is not yet in place, but it is coming fast. Janice explains Bupa's own metamorphosis from health insurer to health organisation, investing heavily in primary and preventive care across medical, dental, optical and psychology clinics, and rolling out AI scribes to its clinicians under strong governance. Simon zooms out to a health system whose old boundaries between payer, provider, acute, primary and consumer care are blurring, driven by digital capability, policy reform and a wave of consolidation. The panel closes on the future of care. They discuss how to equip the next generation of doctors without letting AI become a crutch that erodes clinical judgement, what digital health's US$7.4 billion funding rebound says about capital concentrating into a handful of mega rounds, and why the companies winning big are the ones co-designing with clinicians from day one. Then they imagine the patient journey in 2035, from wellness chairs in autonomous vehicles to consultations that feel, as Janice puts it, more human. Guests Dr Simon Kos is Global Chief Medical Officer at Heidi, the AI clinical documentation company. A physician who practised critical care medicine before moving into digital health, he was previously Global Chief Medical Officer at Microsoft and CEO of Next Practice, and is a long-standing figure in Australian digital health. Dr Janice Tan is a GP and the General Manager of Clinical Innovation at Bupa, where she leads the rollout and piloting of AI solutions across the group's health services. She also advises the RACGP and works to uplift the digital health capability of the GP profession. Chapters 00:00 Introducing the What the Health Wrap 00:07 Guest updates: Heidi's global expansion and life in general practice 03:03 The fortnight's five biggest headlines 05:11 Heidi's Pressure Points report: adopting AI ahead of governance 06:16 Busting the myths about clinicians and technology 10:11 Where general practice is heading: voice by default and deeper consults 13:00 Patients are bringing their own AI to the consult 14:21 Health in ChatGPT and big tech's move into consumer health 18:33 Consumer-grade versus clinical-grade care and the regulation gap 23:41 Bupa's shift from health insurer to health company 30:29 Training the next generation without de-skilling 33:43 Digital health's US$7.4 billion funding landscape 35:31 Finding the wedge: co-designing with clinicians 38:46 The 2035 patient journey 42:46 Rapid fire: emojis, surprises and companies to watch Links and resources Heidi Heidi's Pressure Points 2026 report Bupa Australia Bupa's Connected Care strategy Bupa to acquire Partnered Health Group Health in ChatGPT Rock Health H1 2026 funding and market overview Australia's ban on genetic discrimination in life insurance Claude for Healthcare About the host Emily Casey is the founder of What the Health and host of the What the Health Wrap, making major developments in health technology and innovation easier to understand. The What the Health Wrap is brought to you by What the Health in partnership with Tenmile Ventures . What the Health is part of Day One Network , the podcast and media network from W2D1 Media.
Novartis has agreed to acquire Myricx Bio for up to US$1.5 billion, approximately A$2.2 billion, in a major outcome for a UK biotech company with deep Australian venture backing. In the inaugural What the Health Wrap, host Emily Casey is joined by Dr Jackie Rabec, co-founder and Chief Product Officer at ThinkMD.ai, and Dr Prashanth Rajan, Associate at Brandon Capital, to work through what the fortnight's biggest healthcare stories actually mean. Prashanth explains how Myricx Bio evolved from small-molecule science into a new class of antibody-drug conjugate payloads. He discusses why the proposed acquisition matters for cancer therapeutics, investors and Australia's biotech ecosystem, while cautioning that the ultimate test will still come through clinical development. The conversation then turns to artificial intelligence. Jackie argues that healthcare companies need more than a powerful model. They need a genuine problem, sustainable economics, clinical workflow integration and the change management required for adoption. Prashanth applies the same test to AI drug discovery, where molecular designs must still survive laboratory testing and clinical trials. The panel also examines proposed changes to Australia's R&D Tax Incentive. Under the current proposal, the offset would be refundable for eligible businesses younger than ten years and non-refundable for older businesses. Prashanth explains why that distinction could affect biotech companies just as expensive clinical programs begin to scale, potentially pushing investment, clinical activity and company growth offshore. AdvanCell's US$315 million Series D offers a timely example of what sustained local support can produce. The company is advancing a Lead-212 targeted alpha therapy for metastatic prostate cancer while expanding its isotope supply and manufacturing infrastructure. Finally, the panel asks whether preventive health and longevity represent the future of care or another layer available mainly to people who can afford it. Everlab's A$65 million Series A and Neko Health's US$700 million Series C demonstrate growing demand, but questions remain about equity and whether earlier intervention can reduce pressure on public healthcare systems. Guests Dr Jackie Rabec is co-founder and Chief Product Officer at ThinkMD.ai, which builds offline-capable clinical decision-support tools for frontline health workers. She previously worked at Google and was Head of Product at Heidi Health. Dr Prashanth Rajan is an Associate at Brandon Capital and leads its activities in New South Wales. He has a background in bioinformatics, biochemistry and molecular biology. Chapters 00:00 Introducing the What the Health Wrap 08:07 Myricx Bio's proposed US$1.5 billion acquisition 11:13 Antibody-drug conjugates and Australian biotech 15:35 AI in healthcare beyond administration 24:50 The promise and limits of AI drug discovery 28:46 Proposed changes to Australia's R&D Tax Incentive 35:22 AdvanCell's US$315 million Series D 42:25 Preventive health, longevity and primary care 53:28 Rapid fire: platform risk, companies to watch and useful resources Links and resources ThinkMD.ai: https://www.thinkmd.ai/ Dr Prashanth Rajan at Brandon Capital: https://brandoncapital.vc/team_member/prashanth-rajan/ Myricx Bio acquisition announcement: https://brandoncapital.vc/2026/07/06/brandon-capital-announces-agreement-for-novartis-to-acquire-portfolio-company-myricx-bio-to-advance-new-class-of-cancer-therapeutics/ Australian Treasury's R&D Tax Incentive proposal: https://treasury.gov.au/sites/default/files/2026-06/p2026-781365_0.pdf Claude for Healthcare: https://www.anthropic.com/news/healthcare-life-sciences Chai Discovery's US$400 million Series C: https://www.chaidiscovery.com/news/series-c AdvanCell's US$315 million Series D: https://svhealthinvestors.com/news/advancell-closes-us-315-million-oversubscribed-series-d-financing-to-advance-targeted-alpha-therapies-and-expand-clinical-and-commercial-manufacturing-infrastructure Everlab: https://www.everlab.com.au/ Neko Health's US$700 million Series C: https://www.nekohealth.com/se/en/press/neko-health-raises-usd700m-series-c-ahead-of-us-launch About the host Emily Casey is the founder of What the Health and host of the What the Health Wrap, making major developments in health technology and innovation easier to understand. The What the Health Wrap is brought to you by What the Health in partnership with Tenmile Ventures. What the Health is part of Day One Network, the podcast and media network from W2D1 Media: https://dayone.fm/
Five years of health innovation coverage, millions of reads, and a community of 11,000+. Now finally, What the Health has a podcast too — bringing the content to convos you can now listen to on the go and in video. Host Emily Casey brings the founders, clinicians, investors, operators, and policymakers shaping the future of health into the room for candid, useful, and occasionally unruly conversations. This trailer offers a first taste of the questions the show will tackle. What happens when billions flow into biotech while policy struggles to keep up? How reliable are the latest AI health tools? What can at-home screening change for patients and the wider health system? And when everyone is talking about AI, where is the real advantage? What The Health goes beyond the headlines to work out what is real, what is hype, what is worth paying attention to and why it matters. Expect: candid conversations with leading minds in health innovation clear explanations without the health-speak sharp takes backed by facts practical context on the companies, ideas and policy shifts changing healthcare a smarter way to stay ahead without drowning in noise What The Health is more than a podcast. It is a newsletter, events platform and private community built for people who want to stay switched on to health and health tech. Subscribe to the newsletter and join the What The Health community: https://www.whatthehealth.io/ Follow the show: https://dayone.fm/show/what-the-health-with-emily-casey/ Brought to you by Tenmile. Tenmile partners with teams tackling major unmet needs in human health, helping turn bold ideas and breakthrough science into companies that can improve lives. Learn more: https://www.tenmile.com/ What The Health is part of the Day One Network and produced by W2D1 Media. This podcast is for general information and commentary and is not medical advice.
Five years of health innovation coverage, millions of reads, and a community of 11,000+. Now finally, What the Health has a podcast too — bringing the content to convos you can now listen to on the go and in video. Host Emily Casey brings the founders, clinicians, investors, operators, and policymakers shaping the future of health into the room for candid, useful, and occasionally unruly conversations. This trailer offers a first taste of the questions the show will tackle. What happens when billions flow into biotech while policy struggles to keep up? How reliable are the latest AI health tools? What can at-home screening change for patients and the wider health system? And when everyone is talking about AI, where is the real advantage? What The Health goes beyond the headlines to work out what is real, what is hype, what is worth paying attention to and why it matters. Expect: candid conversations with leading minds in health innovation clear explanations without the health-speak sharp takes backed by facts practical context on the companies, ideas and policy shifts changing healthcare a smarter way to stay ahead without drowning in noise What The Health is more than a podcast. It is a newsletter, events platform and private community built for people who want to stay switched on to health and health tech. Subscribe to the newsletter and join the What The Health community: https://www.whatthehealth.io/ Follow the show: https://dayone.fm/show/what-the-health-with-emily-casey/ Brought to you by Tenmile. Tenmile partners with teams tackling major unmet needs in human health, helping turn bold ideas and breakthrough science into companies that can improve lives. Learn more: https://www.tenmile.com/ What The Health is part of the Day One Network and produced by W2D1 Media. This podcast is for general information and commentary and is not medical advice.
Ranking source
Apple Podcasts rankings via the Mato Topic Intelligence Platform.
Observed September 18, 2026. Cached outside the daily freshness window; the positions keep the date they were taken on.
Apple and Apple Podcasts are trademarks of Apple Inc., registered in the U.S. and other countries.
Pairs with
Bring this source into Mato to read its transferable patterns, then turn them into an original show for your own audience.